Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00217880 · ClinicalTrials.gov registry record · NA

Significance of Biological Markers in Patients With Acute Lung Injury/Acute Respiratory Disease

A NA study of Respiratory Distress Syndrome, Adult, sponsored by University of Michigan.

Completed
Registry status
NA
Development phase
40
Enrollment target
2
Study locations

NCT00217880 is a NA study of Respiratory Distress Syndrome, Adult that has completed, run by University of Michigan. The registered enrollment target is 40 participants, below the 321-participant average among 7 other Respiratory Distress Syndrome, Adult trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00217880, a NA study of Respiratory Distress Syndrome, Adult, has completed, sponsored by University of Michigan.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to identify biological markers of disease in patients with acute lung injury (ALI) that are predictive of either disease susceptibility or prognosis, or that identify novel targets of therapeutic intervention.

Interventions

  • PROCEDURE Bronchoscopy

Study Locations (2)

Georgia

  • Emory University - Atlanta

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2004-07
Est. Completion 2009-06
Phase NA

Sponsor

University of Michigan

1,327 total trials

What the Registry Record Tells You About NCT00217880

The ClinicalTrials.gov registry entry for NCT00217880 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 321-participant average among 7 other Respiratory Distress Syndrome, Adult trials with a reported enrollment target (88% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Respiratory Distress Syndrome, Adult appearing as the primary indexed condition, and to 1 intervention - of which Bronchoscopy is the first listed.

NCT00217880 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, Michigan.

Frequently Asked Questions

What is clinical trial NCT00217880 about?

NCT00217880 is a clinical study titled "Significance of Biological Markers in Patients With Acute Lung Injury/Acute Respiratory Disease". The purpose of this study is to identify biological markers of disease in patients with acute lung injury (ALI) that are predictive of either disease susceptibility or prognosis, or that identify novel targets of therapeutic intervention.

What is the current status of trial NCT00217880?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2004-07. Estimated completion is 2009-06.

What conditions does trial NCT00217880 study?

This clinical trial studies the following conditions: Respiratory Distress Syndrome, Adult.

What interventions are being tested in trial NCT00217880?

The interventions under investigation include: Bronchoscopy (PROCEDURE).

Who is sponsoring clinical trial NCT00217880?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00217880 being conducted?

This trial has 2 study locations across Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Respiratory Distress Syndrome, Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.